Serum Aspartate Aminotransferase, a Novel Potential Biomarker of Prognosis in Extranodal Natural Killer/T Cell Lymphoma, Nasal Type

Overview

Journal Cancer Biomark

Publisher Sage Publications

Specialties Biochemistry
Oncology

Date 2023 Dec 18

PMID 38108343

Authors

Ningning Yao

Qing Hou

Yu Liang

Xin Cao

Bochen Sun

Lijuan Wei

Ruifang Sun

Jianzhong Cao

Affiliations

Soon will be listed here.

Abstract

Background: Aspartate aminotransferase (AST), an indicator of liver cell damage, was related to the prognosis of certain malignant tumors.

Objective: This study examined the predictive value of AST in patients with extranodal natural killer/T cell lymphoma (ENKTL).

Methods: We reviewed 183 cases diagnosed with ENKTL and selected 26 U/L as the optimum cut-off value of AST. We used the univariate and multivariate Cox regression to compare the different AST groups' overall survival (OS) and progression-free survival (PFS).

Results: Prior to propensity score matching (PSM), Kaplan-Meier analysis showed that patients in the low AST subgroup had better OS and PFS than the high AST subgroup. Multivariate analysis revealed that AST was an independent indicator for prognosis. After PSM, the low AST subgroup maintained a significantly better OS and PFS than the high AST subgroup.

Conclusion: AST might represent a significant prognostic marker for ENKTL patients.

References

Kim S, Kim W . Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010; 92(5):690-6. DOI: 10.1007/s12185-010-0720-8. View

Kim T, Heo D . Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009; 100(12):2242-8. PMC: 11159079. DOI: 10.1111/j.1349-7006.2009.01319.x. View

Zhao L, Yang D, Ma X, Liu M, Wu D, Zhang X . The Prognostic Value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for Overall Survival of Hepatocellular Carcinoma Patients Treated with palliative Treatments. J Cancer. 2019; 10(10):2299-2311. PMC: 6584423. DOI: 10.7150/jca.30663. View

Birtle A, Lawton P, Chaundary M, Richman P, McFarlane B . Unexplained high AST in locally advanced breast cancer. Breast J. 2003; 9(6):505-6. DOI: 10.1046/j.1524-4741.2003.09623.x. View

Yang Y, Zhang Y, Zhu Y, Cao J, Yuan Z, Xu L . Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015; 29(7):1571-7. DOI: 10.1038/leu.2015.44. View

Yang Y, Zhu Y, Cao J, Zhang Y, Xu L, Yuan Z . Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015; 126(12):1424-32. DOI: 10.1182/blood-2015-04-639336. View

Pokrovsky V, Vinnikov D . L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis. Expert Rev Anticancer Ther. 2017; 17(8):759-768. DOI: 10.1080/14737140.2017.1344100. View

Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y . L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2008; 88(7):647-52. DOI: 10.1007/s00277-008-0669-3. View

Jin J, Zhu P, Liao Y, Li J, Liao W, He S . Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget. 2015; 6(22):19217-27. PMC: 4662486. DOI: 10.18632/oncotarget.4265. View

10.

Lee J, Suh C, Park Y, Ko Y, Bang S, Lee J . Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2005; 24(4):612-8. DOI: 10.1200/JCO.2005.04.1384. View

11.

Scherzer R, Heymsfield S, Rimland D, Powderly W, Tien P, Bacchetti P . Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection. AIDS. 2016; 31(1):71-79. PMC: 5127775. DOI: 10.1097/QAD.0000000000001278. View

12.

Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R . The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma. J Urol. 2015; 194(1):30-5. DOI: 10.1016/j.juro.2015.01.083. View

13.

Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U . Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2003; 103(7):2474-9. DOI: 10.1182/blood-2003-09-3080. View

14.

Kim S, Yoon D, Jaccard A, Chng W, Lim S, Hong H . A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17(3):389-400. DOI: 10.1016/S1470-2045(15)00533-1. View

15.

. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14):987-94. DOI: 10.1056/NEJM199309303291402. View

16.

Cao J, Lan S, Shen L, Si H, Xiao H, Yuan Q . Hemoglobin level, a prognostic factor for nasal extranodal natural killer/T-cell lymphoma patients from stage I to IV: A validated prognostic nomogram. Sci Rep. 2017; 7(1):10982. PMC: 5591293. DOI: 10.1038/s41598-017-11137-9. View

17.

Kim W, Song S, Ahn Y, Ko Y, Baek C, Kim D . CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol. 2001; 12(3):349-52. DOI: 10.1023/a:1011144911781. View

18.

Au W, Weisenburger D, Intragumtornchai T, Nakamura S, Kim W, Sng I . Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 113(17):3931-7. DOI: 10.1182/blood-2008-10-185256. View

19.

Chim C, Ma S, Au W, Choy C, Lie A, Liang R . Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2003; 103(1):216-21. DOI: 10.1182/blood-2003-05-1401. View

20.

Yoon D, Kim S, Jeong S, Shin D, Bae S, Hong J . Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget. 2016; 7(51):85584-85591. PMC: 5356760. DOI: 10.18632/oncotarget.11319. View